Floatz logo

Cytosin-Arabinosid

Burkitt's Leukemia

Nicola GoekbugetPhase 4 / ApprovedDormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Burkitt's Leukemia cohort.

Asset / SponsorPhaseRating
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Nicola Goekbuget
Phase 4BB
VINDESINE
Nicola Goekbuget
Phase 4BB
Ifosfamide
Nicola Goekbuget
Phase 4BB
ETOPOSIDE
Nicola Goekbuget
Phase 4BB
Inno-206
Nicola Goekbuget
Phase 4BB

View all 11 →

Same molecule, other indications

Cytosin-Arabinosid is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →